TCM Biotech International Corp. (TPEX:4169)
Taiwan · Delayed Price · Currency is TWD 170.00
-8.50 (-4.76%)
Mar 24, 2026, 1:59 PM CST
TCM Biotech International Revenue
In the year 2025, TCM Biotech International had annual revenue of 685.49M TWD with 2.84% growth. TCM Biotech International had revenue of 174.99M in the quarter ending December 31, 2025, with 1.80% growth.
Revenue
685.49M
Revenue Growth
+2.84%
P/S Ratio
15.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.49M | 18.96M | 2.84% |
| Dec 31, 2024 | 666.53M | -303.09M | -31.26% |
| Dec 31, 2023 | 969.62M | 167.20M | 20.84% |
| Dec 31, 2022 | 802.42M | 100.38M | 14.30% |
| Dec 31, 2021 | 702.05M | -35.03M | -4.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.20B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| PharmaEngine | 911.42M |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| Tanvex BioPharma | 400.97M |
| TaiGen Biopharmaceuticals Holdings | 259.47M |